Med-tech startup Innovodigm raises seed funding round led by IAN Group

Med-tech startup Innovodigm has raised Rs 5.5 crore in a seed funding round led by the IAN Group. IAN contributed Rs 4.5 crore, with the remaining amount invested by PadUp Ventures.

The proceeds will be utilized  for process optimization, infrastructure scaling, and team expansion to support third-party preclinical validation and prepare for upcoming clinical trials, Innovodigm said in a press release.

Co-founded in 2020 by Jhimli Manna and  Ayan Chatterjee,  Innovodigm develops micro-array patches for vaccines, offering a transformative alternative to traditional injectable immunizations. Designed to overcome challenges such as cold-chain dependency, medical waste, and needle-stick injuries, the MAP uses thermostabilized vaccines that remain viable for up to 120 days at 40°C, eliminating the need for refrigeration and enabling outreach to remote, underserved areas.

Innovodigm says that the MAP platform has garnered notable recognition, including selection as a Top 2 Technology at the Nano Electronics Showcase 2025 by the Ministry of Electronics & IT. The company has signed a Material Transfer Agreement (MTA) with a leading Indian vaccine manufacturer for third-party validation, with clinical trials scheduled to commence next year.

 “Spinning out from IIT Kharagpur’s Microelectronics and MEMS Lab has been fundamental to our scientific foundation. Our MAP platform reflects India’s ability to lead in affordable, scalable vaccine delivery that serves both national and global public health goals,” said  Jhimli Manna, CEO of Innovodigm.

With plans to expand across India and other low- and middle-income countries, Innovodigm aims to adapt its patch for various vaccines, including measles, hepatitis, flu, and COVID-19 boosters. The company is also working on building local manufacturing hubs so that patches can be made closer to where they’re needed most.